Astrocytic C–X–C motif chemokine ligand-1 mediates β-amyloid-induced synaptotoxicity
Open Access
- 28 December 2021
- journal article
- research article
- Published by Springer Nature in Journal of Neuroinflammation
- Vol. 18 (1) , 1-17
Abstract
Background: Pathological interactions between β-amyloid (Aβ) and tau drive synapse loss and cognitive decline in Alzheimer’s disease (AD). Reactive astrocytes, displaying altered functions, are also a prominent feature of AD brain. This large and heterogeneous population of cells are increasingly recognised as contributing to early phases of disease. However, the contribution of astrocytes to Aβ-induced synaptotoxicity in AD is not well understood. Methods: We stimulated mouse and human astrocytes with conditioned medium containing concentrations and species of human Aβ that mimic those in human AD brain. Medium from stimulated astrocytes was collected and immunodepleted of Aβ before being added to naïve rodent or human neuron cultures. A cytokine, identified in unbiased screens of stimulated astrocyte media and in postmortem human AD brain lysates was also applied to neurons, including those pre-treated with a chemokine receptor antagonist. Tau mislocalisation, synaptic markers and dendritic spine numbers were measured in cultured neurons and organotypic brain slice cultures. Results: We found that conditioned medium from stimulated astrocytes induces exaggerated synaptotoxicity that is recapitulated following spiking of neuron culture medium with recombinant C–X–C motif chemokine ligand-1 (CXCL1), a chemokine upregulated in AD brain. Antagonism of neuronal C–X–C motif chemokine receptor 2 (CXCR2) prevented synaptotoxicity in response to CXCL1 and Aβ-stimulated astrocyte secretions. Conclusions: Our data indicate that astrocytes exacerbate the synaptotoxic effects of Aβ via interactions of astrocytic CXCL1 and neuronal CXCR2 receptors, highlighting this chemokine–receptor pair as a novel target for therapeutic intervention in AD.Keywords
All Related Versions
Funding Information
- Alzheimer’s Research UK (ARUK-RF2014-2, ARUK-EG2013-B1, ARUK-PhD2018-002, PG2019A-003)
- Van Geest Charitable Trust (BGPN)
- Consejo Nacional de Investigaciones Científicas y Técnicas (IV)
- Medical Research Council (MR/N022696/1)
- Academy of Medical Sciences UK (SBF002/1142)
- Fondation Thierry Latran (LF)
This publication has 78 references indexed in Scilit:
- Astrocyte Senescence as a Component of Alzheimer’s DiseasePLOS ONE, 2012
- Distinct Dendritic Spine and Nuclear Phases of Calcineurin Activation after Exposure to Amyloid-β Revealed by a Novel Fluorescence Resonance Energy Transfer AssayJournal of Neuroscience, 2012
- Neurotoxicity of Amyloid -Protein: Synaptic and Network DysfunctionCold Spring Harbor Perspectives in Medicine, 2012
- Neuropathological Alterations in Alzheimer DiseaseCold Spring Harbor Perspectives in Medicine, 2011
- Astrocytes are important mediators of Aβ-induced neurotoxicity and tau phosphorylation in primary cultureCell Death & Disease, 2011
- Tau Mislocalization to Dendritic Spines Mediates Synaptic Dysfunction Independently of NeurodegenerationNeuron, 2010
- Amyloid β Induces the Morphological Neurodegenerative Triad of Spine Loss, Dendritic Simplification, and Neuritic Dystrophies through Calcineurin ActivationJournal of Neuroscience, 2010
- X11 rescues memory and long-term potentiation deficits in Alzheimer's disease APPswe Tg2576 miceHuman Molecular Genetics, 2009
- Amyloid-β protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memoryNature Medicine, 2008
- Natural oligomers of the amyloid-β protein specifically disrupt cognitive functionNature Neuroscience, 2004